This study is designed to explore the efficacy and safety of Telitacicept combined with low-dose steroids for the treatment of refractory MG, and to investigate related biomarkers such as immunoglobulins, BlyS/APRIL, and AChR-Ab titers, in order to clarify whether Telitacicept can rapidly and effectively help achieve MG treatment goals and assist in steroid reduction.

开始日期2024-12-01

申办/合作机构

First Affiliated Hospital of Wenzhou Medical University

NCT06510283 / Recruiting临床2期IIT

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
Through this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.

开始日期2024-12-01

申办/合作机构

首都医科大学附属北京同仁医院

NCT06654596 / Not yet recruitingN/AIIT

A Multicenter, Randomized, Controlled Clinical Study on the Efficacy and Safety of Telitacicept in Patients with IgA Nephropathy

A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.

开始日期2024-11-01

申办/合作机构

上海交通大学医学院附属瑞金医院

[+7]

100 项与泰它西普相关的临床结果

登录后查看更多信息

100 项与泰它西普相关的转化医学

登录后查看更多信息

100 项与泰它西普相关的专利（医药）

登录后查看更多信息

项与泰它西普相关的文献（医药）

2024-11-01·Clinical Case Reports

Single‐dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series

Article

作者: Sun, Liping ; Zhang, Xinzhou ; Chen, Fuce

Key Clinical Message:

We report three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. These cases illustrates the telitacicept may offer new hope for the treatment of IMN.

Abstract:

Despite the variety of treatment options available, effective therapies for refractory membranous nephropathy remain lacking. Recently, some reports have suggested that telitacicept is a new therapeutic option. However, only a few published studies have documented the use of telitacicept for treating idiopathic membranous nephropathy (IMN). We present three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments, including glucocorticoids, tacrolimus, mycophenolate mofetil, cyclophosphamide, cyclosporine, and rituximab. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. Thus, telitacicept may offer new hope for the treatment of refractory membranous nephropathy.

2024-11-01·Heliyon

Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review

Article

作者: Pan, Xin ; Xie, Lili ; Sui, Xiaowen ; Liu, Chang ; Li, Furong ; Ma, Shubei ; Zhao, Hongling

Background:

Neuromyelitis optica spectrum disorders (NMOSD) is characterized by inflammatory demyelinating events in the central nervous system (CNS), primarily affecting the spinal cord and optic nerve, with a significant influence of astrocytes. Longitudinal extensive transverse myelitis (LETM) is a distinct and relatively rare spinal cord syndrome, commonly associated with NMOSD.

Case presentation:

This report describes a unique case of myelitis in a patient diagnosed with NMOSD. The patient exhibited an uncommon manifestation of ultra- LETM (u-LETM), coexisting with connective tissue disorders including Sjögren's syndrome and autoimmune hepatitis-primary cholestatic cirrhosis. In the acute phase, high-dose methylprednisolone pulse therapy was administered in combination with intravenous human immunoglobulin, while prednisone was gradually tapered and discontinued upon stabilization of the patient's condition. Simultaneously, sequential disease-modifying therapy was initiated, starting with long-term oral administration of mycophenolate mofetil, followed by cyclophosphamide, telitacicept, and Inebilizumab. During follow-up visits conducted every three months, the patient showed gradual improvement, eventually achieving the ability to stand and walk independently.

Conclusions:

Early and comprehensive evaluation of autoimmune diseases is crucial in patients with NMOSD presenting with u-LETM as the initial symptom. Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis.

2024-10-01·Clinical Kidney Journal

Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case–control study

Article

作者: Ma, Jianfei ; Yao, Li ; Fan, Yi ; Wang, Meng

ABSTRACT:

Background:

Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, has recently been used in autoimmune diseases. We assessed the efficacy and safety of telitacicept in immunoglobulin A nephropathy (IgAN) patients.

Methods:

This study included 42 IgAN patients who received telitacicept treatment, forming the ‘whole telitacicept group’. Among them, 20 patients who had not previously received corticosteroid (CS) therapy or immunosuppressive (IS) agents were categorized as the ‘newly treated telitacicept subgroup’. Additionally, 28 patients who were selected to match historical controls received conventional IS therapy (CS therapy with/without IS agents) and were classified as the ‘conventional IS group’. Telitacicept was partially used in combination with conventional IS therapy, including initial CS in different doses. Various indicators were compared at 4-week intervals up to 24 weeks among the three groups.

Results:

After 24 weeks of treatment, the 24-hour proteinuria decreased from 1.70 g [interquartile range (IQR) 1.05–2.58] to 0.21 g (IQR 0.39–0.13) (P = .043) in the newly treated telitacicept subgroup, from 1.78 g (IQR 0.97–2.82) to 0.44 g (IQR 1.48–0.16) (P = .001) in the conventional IS group and from 1.07 g (IQR 0.66–1.99) to 0.26 g (IQR 0.59–0.17) (P = .028) in the whole telitacicept group. The estimated glomerular filtration rate (eGFR) increased from 76.58 ± 30.26 ml/min/1.73 m2 to 80.30 ± 26.76 ml/min/1.73 m2 (P = .016) in the newly treated telitacicept subgroup, from 72.73 ± 33.41 ml/min/1.73 m2 to 84.08 ± 26.81 ml/min/1.73 m2 (P = .011) in the conventional IS group and from 70.10 ± 32.88 ml/min/1.73 m2 to 71.21 ± 31.49 ml/min/1.73 m2 (P = .065) in the whole telitacicept group. During follow-up periods, the efficacy rates of the three groups did not show statistically significant differences and no serious adverse events were observed.

Conclusions:

Telitacicept may be a safe and effective treatment for IgAN, offering reductions in proteinuria and increases in eGFR similar to conventional IS therapy. After a 24-week follow-up, the incidence of adverse events was lower for telitacicept than for conventional IS therapy.

410

项与泰它西普相关的新闻（医药）

2024-12-12

·荣昌生物

重磅首发！维迪西妥单抗治疗HER2阳性存在肝转移的晚期乳腺癌患者III期临床研究数据公布｜2024 SABCS

当地时间12月12日上午，在第47届圣安东尼奥乳腺癌研讨会（SABCS）“新型HER2疗法”的重要壁报专场（Poster Spotlight Sessions），荣昌生物首次对外公布了维迪西妥单抗治疗HER2阳性存在肝转移的晚期乳腺癌患者Ⅲ期临床研究数据，这是全球首个证实HER2 ADC在HER2阳性存在肝转移的晚期乳腺癌患者中取得阳性结果的确证性Ⅲ期研究，中国医学科学院肿瘤医院王佳玉教授作汇报讨论。SABCS是乳腺癌研究领域规模最大、最具影响力的年度盛会之一，此项重磅研究成果的公布吸引了全球专家学者的关注。数据显示，约45%的HER2阳性晚期乳腺癌患者伴有肝转移，预后较差，5年生存率仅为8%~12%。此次公布的是一项随机、开放、多中心的Ⅲ期临床研究，旨在评价维迪西妥单抗对比拉帕替尼联合卡培他滨治疗HER2阳性存在肝转移的晚期乳腺癌患者的有效性和安全性，共纳入了104名患者，既往均接受过曲妥珠单抗和紫杉醇治疗。截至2023年12月31日（中位随访17.2个月），此研究最终分析结果显示： • 根据独立审查委员会（IRC）评估，与拉帕替尼联合卡培他滨相比，维迪西妥单抗显著延长了患者的无进展生存期（PFS），疾病进展或死亡风险降低了44%。中位PFS分别为9.9vs4.9个月，风险比[HR]=0.56 [95% CI：0.35-0.90]），双侧P=0.0143。安全性数据与已知风险相似，安全性可控。 • 总生存期（OS）数据尚不成熟，虽然拉帕替尼联合卡培他滨组有21例患者疾病进展后接受维迪西妥单抗治疗，但已观察到维迪西妥单抗组有明显的总生存期（OS）获益趋势，两组中位OS分别为NE vs 25.92个月（HR=0.56, 95%CI: 0.25-1.29）。 “这是第一个证实HER2靶向ADC在HER2阳性存在肝转移的晚期乳腺癌患者中具有显著疗效的Ⅲ期确证性研究。”王佳玉教授表示，维迪西妥单抗对比拉帕替尼联合卡培他滨改善了患者的无进展生存期，且显示出良好的生存获益趋势，安全性可控，有望为既往接受过曲妥珠单抗和紫杉醇治疗的HER2阳性存在肝转移的晚期乳腺癌患者提供更精准、强效、安全的新的治疗选择。维迪西妥单抗用于既往接受过曲妥珠单抗或其生物类似物和紫衫类药物治疗的HER2阳性（HER2免疫组织化学检查结果为3+或FISH+）存在肝转移的晚期乳腺癌患者的适应症上市申请已于今年10月获得国家药品监督管理局药品审评中心(CDE)受理，并基于此前的突破性疗法认定，被纳入优先审评审批程序。文稿 | 危颖编辑 | 春媛荣昌生物科创板上市 | 港交所上市挺进医保 | License out 维迪西妥单抗 | 泰它西普 RC28 | RC108 | RC118

临床3期抗体药物偶联物优先审批突破性疗法临床结果

2024-12-11

·荣昌生物

解燃眉之急，让爱心延续 | 一场跨越1600公里的暖心接力

REMEGEN 编者按 17岁的小朱和小马（均化名）是两位重庆的“特殊”患者，分别患有系统性红斑狼疮和幼年特发性关节炎。多年来，两位年轻患者尽管承受着身体和经济的双重压力，却一直以阳光心态积极应对疾病。荣昌生物知悉并深入了解患者家庭情况后，迅速启动了援助机制，携手烟台市红十字会将急需药物送到了患者手中。这次跨越山海的爱心传递得到了重庆、山东两地主流媒体的重点关注，第1眼TV-华龙网、《大众日报》、烟台市融媒体中心分别对事件进行了深入报道。 12月3日，在重庆医科大学附属儿童医院两江院区的风湿免疫科，室外细雨霏霏，室内却暖意融融。从黄渤海之滨到长江沿岸渝北，一场跨越1600多公里的爱心接力传递着新的希望。来自烟台的创新药企荣昌生物通过烟台市红十字会向长期饱受病痛折磨的患儿小朱和小马（均为化名）分别捐赠了48支“泰它西普”，以支持他们接下来半年的治疗。 “孩子于2016年患系统性红斑狼疮，长达8年多的治疗已经让我们负债越来越多。”小朱的妈妈说，“即便是如此，孩子的病情依然不稳定。”转机发生在2023年，小朱的主治医生唐雪梅教授在全面诊断评估患者病情后，加用泰它西普，一年多后，小朱病情得到了控制。“然而，我们实在无法承担这笔费用，无奈之下向荣昌生物发出了求助信。”得知消息后，荣昌生物迅速相应，协调各方资源，最终促成了这次捐赠活动。另一名患有幼年特发性关节炎的患者小马，家住重庆市忠县某村，在过去他一直凌晨3点就从家出发赶去医院，两地辗转求医问药。“孩子的爸爸是普通建筑工人，利用空余时间四处兼职，妈妈在食堂工作，家庭收入微薄。孩子属于难治性幼年特发性关节炎，最近几年常规药物和常规生物制剂效果不佳，唐医生建议尝试泰它西普，给我们带来了新的希望”小马的姑妈说。捐赠仪式上，重庆医科大学附属儿童医院风湿免疫科副主任安云飞教授介绍，团队聚焦儿童风湿免疫性疾病防治体系构建，为目前国内规模最大的儿童风湿免疫疾病诊治中心，今年被评为国家临床重点专科建设科室。他说：“狼疮、关节炎在我们科室是常见病，小朱和小马这两名患者刚入院时均处于疾病显著活动状态。以前常讲狼疮的5年生存率，现在随着新的生物制剂的出现，孩子们大多能获得有效控制，都讲达标治疗了，这些孩子规范治疗后可以像正常人一样生活，上大学、结婚、生子、做医生、做科学家……从前激素治疗的副作用在儿童身上特别突出，会影响孩子的生长发育，以及代谢紊乱等，泰它西普的显著疗效和安全性已在临床上得到证明，且有助于减少激素的使用，可谓‘国货之光’。相信随着临床数据的增多，会有更好的应用。”他表示，希望以本次活动为契机，让患儿用上好药，给孩子们带来更大程度的帮助。荣昌生物区域销售总监高波鼓励两位患者树立战胜疾病的信心，并表示非常欣慰看到很多患者在泰它西普的规范治疗下，维持长期稳定的状态，回归到正常的生活，而这正体现了荣昌生物的社会责任。希望我国近100万的系统性红斑狼疮的患者，都能够得到疗效好、副作用小的规范治疗。烟台市红十字会工作人员表示，感谢荣昌生物积极承担社会责任，此次大爱善举弘扬了“人道博爱奉献”的红十字精神，同时也感谢医院以医者仁心传递仁爱，并希望患者能够振奋精神，积极治疗，早日走出困境。接到捐赠药品后，小朱的妈妈热泪盈眶的说：“太感谢你们了！我会坚定地陪孩子走下去，尽自己最大努力回报社会，让这份爱延续！” 播撒爱的种子，让爱心永续。提起对未来的打算，两名正在读高三的孩子不约而同地表示，想要成为治病救人的医生，用实际行动回馈爱心企业，为更多有需要的人解除病痛。文稿 | 危颖摄像 | 连鹏编辑 | 春媛荣昌生物科创板上市 | 港交所上市挺进医保 | License out 维迪西妥单抗 | 泰它西普 RC28 | RC108 | RC118

2024-12-03

·PRNewswire

Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D. Heightened awareness and robust support from governments and key industry players further create a dynamic environment for innovation and better patient outcomes. LAS VEGAS, Dec. 3, 2024 /PRNewswire/ -- DelveInsight's ' Lupus Nephritis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline lupus nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the lupus nephritis pipeline domain. Key Takeaways from the Lupus Nephritis Pipeline Report DelveInsight's lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for lupus nephritis treatment. Key lupus nephritis companies such as AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others are evaluating new lupus nephritis drugs to improve the treatment landscape. Promising lupus nephritis pipeline therapies such as Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others are under different phases of lupus nephritis clinical trials. In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases. In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease. In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report The lupus nephritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lupus nephritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lupus nephritis clinical trial landscape. Lupus Nephritis Overview Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that can affect multiple organ systems. In lupus nephritis, the immune system mistakenly attacks the kidneys, leading to inflammation and damage. The exact cause is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors, including infections and exposure to certain drugs or UV light. Symptoms of lupus nephritis can vary but often include swelling in the legs and feet, high blood pressure, foamy urine, and in severe cases, hematuria. Patients may also experience fatigue, joint pain, and skin rashes, typical of lupus. Diagnosis usually involves a combination of blood tests, urinalysis, and imaging studies. A kidney biopsy may be necessary to evaluate the extent of kidney damage and guide treatment. Treatment for lupus nephritis aims to reduce inflammation and prevent kidney damage. It often involves corticosteroids and immunosuppressive medications such as mycophenolate mofetil or azathioprine. In severe cases, more aggressive treatments, including cyclophosphamide or biologic therapies like belimumab, may be utilized. Regular monitoring of kidney function and overall health is crucial for managing the disease effectively. Find out more about lupus nephritis treatment drugs @ Drugs for Lupus Nephritis Treatment A snapshot of the Lupus Nephritis Pipeline Drugs mentioned in the report: Learn more about the emerging lupus nephritis pipeline therapies @ Lupus Nephritis Clinical Trials Lupus Nephritis Therapeutics Assessment The lupus nephritis pipeline report proffers an integral view of the lupus nephritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Lupus Nephritis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Interferon alpha-beta receptor antagonists, Cell death inhibitors, Cell death stimulants, Antibody-dependent cell cytotoxicity, B-cell activation factor receptor antagonists, Glucokinase stimulants, Dendritic cell inhibitors, Complement factor D inhibitors, Complement C3 inhibitors, Proteasome inhibitors, Natural killer cell replacements, Immunologic cytotoxicity; T lymphocyte replacements Key Lupus Nephritis Companies: AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others. Key Lupus Nephritis Pipeline Therapies: Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others. Dive deep into rich insights for new drugs for lupus nephritis treatment, visit @ Lupus Nephritis Drugs Table of Contents For further information on the lupus nephritis pipeline therapeutics, reach out @ Lupus Nephritis Treatment Drugs Related Reports Lupus Nephritis Epidemiology Lupus Nephritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted lupus nephritis epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, CABALETTA BIO, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床申请

100 项与泰它西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L04AA	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
类风湿关节炎	中国	荣昌生物制药（烟台）股份有限公司	2024-07-16
系统性红斑狼疮	中国	荣昌生物制药（烟台）股份有限公司	2021-03-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重症肌无力	申请上市	中国	荣昌生物制药（烟台）股份有限公司	2024-10-26
原发性干燥综合征	临床3期	中国	荣昌生物制药（烟台）股份有限公司	2023-04-03
免疫球蛋白a肾病	临床3期	美国	荣昌生物制药（烟台）股份有限公司	2022-11-18
视神经脊髓炎	临床3期	中国	荣昌生物制药（烟台）股份有限公司	2018-01-12
狼疮性肾炎	临床2期	中国	荣昌生物制药（烟台）股份有限公司	2023-04-17
复发-缓解型多发性硬化	临床2期	中国	荣昌生物制药（烟台）股份有限公司	2021-05-13
膜性肾小球肾炎	临床1期	中国	荣昌生物制药（烟台）股份有限公司	-
肾病	临床申请批准	中国	荣昌生物制药（烟台）股份有限公司	2024-07-22
免疫球蛋白G4相关疾病	临床申请批准	中国	荣昌生物制药（烟台）股份有限公司	2024-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NEWS 人工标引	N/A	免疫球蛋白a肾病	-	Telitacicept	淵夢網遞鏇鹽鹽鹽簾鬱(襯膚獵製積醖廠積鏇窪) = 廠鹹壓膚窪鬱繭餘選壓獵鬱窪構製範鹽壓鏇齋 (廠獵夢糧構築顧廠顧遞 ) 更多	积极	2024-11-15
				Supportive treatment	淵夢網遞鏇鹽鹽鹽簾鬱(襯膚獵製積醖廠積鏇窪) = 鹹範觸範憲窪憲鹽鹹鹹獵鬱窪構製範鹽壓鏇齋 (廠獵夢糧構築顧廠顧遞 ) 更多
NCT02885610 (Pubmed \| Ann Rheum Dis) 人工标引	临床2期	系统性红斑狼疮	249	Telitacicept 80 mg	窪衊網淵範淵獵淵鑰窪(餘齋獵襯襯遞衊顧簾繭) = 醖簾壓製築遞築夢網獵艱獵積簾鑰築積顧衊憲 (繭簾鬱鏇選遞廠鑰衊製 )	积极	2024-04-01
				Telitacicept 160 mg	窪衊網淵範淵獵淵鑰窪(餘齋獵襯襯遞衊顧簾繭) = 鏇願膚醖憲壓選構積艱艱獵積簾鑰築積顧衊憲 (繭簾鬱鏇選遞廠鑰衊製 )
NCT04078386 (Literature) 人工标引	临床2期	原发性干燥综合征	42	telitacicept 160 mg	淵蓋築繭衊築簾夢壓製(觸衊糧觸繭淵顧壓獵窪) = None 鹽選艱壓鹽襯網鑰窪膚 (襯獵齋壓鏇鑰顧鹹構鹹 ) 更多	积极	2024-03-01
				telitacicept 240 mg
NCT03016013 (ACR2023) 人工标引	临床3期	类风湿关节炎	479	Telitacicept 160 mg	蓋選壓簾繭鬱膚鬱襯膚(積淵鹹齋選鏇積網淵網) = 衊繭遞遞餘觸選夢構艱獵願簾衊選憲構觸範鬱 (襯齋襯憲壓鏇壓鏇繭範 ) 更多	积极	2023-10-24
				Placebo	蓋選壓簾繭鬱膚鬱襯膚(積淵鹹齋選鏇積網淵網) = 顧鏇夢構壓鹽顧鬱積壓獵願簾衊選憲構觸範鬱 (襯齋襯憲壓鏇壓鏇繭範 ) 更多
NCT04078386 (Corporate Publications) 人工标引	临床2期	原发性干燥综合征	42	placebo	壓窪膚鹹鬱鹽膚製簾獵(觸餘窪願簾築夢餘憲鏇) = 構齋廠繭襯壓構範襯遞廠鑰廠淵衊膚膚願齋憲 (繭鹽糧遞鹽糧窪艱積糧, 4.55)	积极	2023-07-17
				Telitacicept 160 mg	壓窪膚鹹鬱鹽膚製簾獵(觸餘窪願簾築夢餘憲鏇) = 網窪廠壓齋構簾窪壓遞廠鑰廠淵衊膚膚願齋憲 (繭鹽糧遞鹽糧窪艱積糧, 2.73)
EULAR2023	临床3期	系统性红斑狼疮 ANA/anti-dsDNA \| C3 \| C4 ... 更多	335	Telitacicept 160 mg	觸壓選襯製餘觸顧築網(獵餘夢齋選網鹹鬱觸製) = 憲鬱選襯製壓範選夢構鑰遞艱構蓋選窪窪鹽衊 (積範鹽餘鏇繭製襯網鹹 )	积极	2023-05-31
				Placebo	觸壓選襯製餘觸顧築網(獵餘夢齋選網鹹鬱觸製) = 廠夢積膚願衊簾夢選廠鑰遞艱構蓋選窪窪鹽衊 (積範鹽餘鏇繭製襯網鹹 )
Pubmed 人工标引	N/A	系统性红斑狼疮	20	Telitacicept	積簾壓構夢獵淵鹹鏇衊(夢廠觸夢製壓遞獵願積) = 遞窪膚遞鹽範繭憲選襯構鏇膚醖願鬱築糧鏇醖 (糧鹹醖衊鹽衊範膚衊窪 ) 更多	积极	2022-11-23
NCT04302103 (Corporate Publications) 人工标引	临床2期	重症肌无力	29	泰它西普 (160mg)	鹽積窪窪築選衊襯餘糧(蓋衊衊築壓艱襯顧鏇網) = 鬱憲夢網壓簾網襯醖顧製鏇獵憲積醖餘襯憲繭 (壓窪齋醖糧膚願鹹製選 )	积极	2022-10-31
				泰它西普 (240mg)	鹽積窪窪築選衊襯餘糧(蓋衊衊築壓艱襯顧鏇網) = 齋鬱鹽製遞壓衊淵廠淵製鏇獵憲積醖餘襯憲繭 (壓窪齋醖糧膚願鹹製選 )
NCT05306574 (Biospace) 人工标引	临床3期	系统性红斑狼疮	335	Standard of Care+Telitacicept	鏇鹹蓋顧壓鑰廠積願壓(構構壓鬱網齋餘構鹹鏇) = 築夢壓糧鹽餘襯廠壓構窪衊顧積壓衊鬱範襯獵 (顧積網鏇範膚網窪鹹構 )	积极	2022-09-19
				Standard of Care+Placebo	鏇鹹蓋顧壓鑰廠積願壓(構構壓鬱網齋餘構鹹鏇) = 艱衊鏇構憲蓋醖糧衊繭窪衊顧積壓衊鬱範襯獵 (顧積網鏇範膚網窪鹹構 )